Actively Recruiting
IV Ketamine vs. IN Esketamine for MDD TRD
Led by Gustavo Vazquez · Updated on 2024-07-10
80
Participants Needed
1
Research Sites
187 weeks
Total Duration
On this page
Sponsors
G
Gustavo Vazquez
Lead Sponsor
C
Centre for Addiction and Mental Health
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the comparative acute effects of ketamine vs esketamine in participants over the age of 18 for the treatment of their severe depression and suicidal ideations. Participants are already taking antidepressants and/or antipsychotics as part of their regular medical care for depression,
CONDITIONS
Official Title
IV Ketamine vs. IN Esketamine for MDD TRD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult outpatients aged 18 to 75 years
- Diagnosed with unipolar major depressive disorder as defined by DSM-5
- Experiencing major depressive episodes characterized as treatment-resistant depression
- Have experienced at least two previous failed antidepressant treatments of adequate dose and duration for the current episode
You will not qualify if you...
- Diagnosis of psychosis
- Main diagnosis of personality disorder
- Uncontrolled hypertension
- Substance abuse
- Currently pregnant or breastfeeding
- Previous negative reaction to ketamine or esketamine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Providence Care Hospital
Kingston, Ontario, Canada, K7L4X3
Actively Recruiting
Research Team
G
Gustavo H Vazquez, MD,PhD,FRCPC
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here